Deadline for Abstract Submission: | Wednesday, May 8, 2024 Wednesday, May 15, 2024 Wednesday, May 22, 2024 |
*The call for abstracts has closed.
The 61st Annual Meeting of Japanese Society of Pediatric Allergy and Clinical Immunology (JSPACI) welcomes all delegates to submit their abstracts to be considered for presentation.
Abstract Submission Guidelines
- Language: English.
- Title, Affiliation, Name, Abstract (Please prepare your data in this order)
- The title of abstract must be within 200 characters including spaces.
- The body of abstract should NOT exceed 1,100 characters including spaces.
- Tables and images are NOT allowed.
- Abstract Structure: Purpose-Methods-Results-Conclusions
- *
- After submitting the abstract, you will receive an E-mail confirming the receipt of your abstract. If you do not receive this e-mail, please contact the congress secretariat. (61jspaci[A]convention[D]co[D]jp (Please change [A]to @ and [D] to .))
- Each initial letter of the name or title should be capitalized, and other letters should be in lowercase. Please do not omit words and phrases.
- Submissions for I-PAS session must be submitted online. Please click on "New submission" below.
- First authors should be the presenting author and should handle all communication with the secretariat.
- First author's full name, country, name of the institution, telephone number and e-mail address should be filled in the abstract submission form.
- First authors from overseas are required to submit CV and Letter of recommendation from your coach or trainer in English.
Topics and Presentation Styles
Please select a topic which is most applicable to your study. Accepted abstracts should be orally presented in English at I-PAS session on site.
Please note that the organizing committee of the 61st Annual Meeting of Japanese Society of Pediatric Allergy and Clinical Immunology will make the final decision if the abstract is accepted.
Topics
01 | Atopy: Prediction and prevention | 02 | Allergy march |
---|---|---|---|
03 | Atopic dermatitis | 04 | Urticaria and angioedema |
05 | Asthma: Diagnosis | 06 | Asthma: Treatment |
07 | Rhinitis and sinusitis | 08 | Food allergy: Diagnosis |
09 | Food allergy: Treatment | 10 | Anaphylaxis |
11 | Adverse reaction to drugs | 12 | Allergy diagnosis (in vitro and in vivo) |
13 | Environment: Indoor and outdoor | 14 | Immunotherapy |
15 | Pharmacotherapy | 16 | Patient Education |
17 | Allergen | 18 | IgE |
19 | BHR and lung function etc | 20 | Genetics and pharmacogenetics |
21 | Mediators and antagonists | 22 | Cells involved in allergic diseases |
23 | Cytokines and chemokines | 24 | Immunodeficiency disorders |
25 | Immunity | 26 | Clinical immunology and autoimmune disorders |
27 | Airway disease | 28 | Upper and lower airway infection |
29 | Animal model of disease | 30 | Others |
Acceptance Notification
Abstracts will be reviewed and selected by the organizing committee of the 61st Annual Meeting of Japanese Society of Pediatric Allergy and Clinical Immunology. Authors will be notified of selection by e-mail in August, 2024.
Abstract withdrawal
Abstract modification is possible until submission deadline. If you have to withdraw the abstract after the deadline, please inform the secretariat by E-mail by June 30, 2024.
Publication of abstracts
Accepted abstracts will be published in the Nihon Shoni Arerugi Gakkaishi(The Japanese Journal of Pediatric Allergy and Clinical Immunology).
Ethical Guidelines
- The abstract must be based on scientific evidence and be consistent with the content of the abstract.
- The abstract presentation is not intended for commercial use.
- COI status must be disclosed in accordance with the "Common Guidelines on Conflict of Interest (COI) in Medical Research" and its detailed regulations.
- The authors are responsible for giving sufficient consideration to the protection of privacy.
- The study reported in the abstract involved human subjects and it meets the ethical principles of the Declaration of Helsinki.
- With the exception of case reports of less than five cases, the abstract of human research must be been approved by the Ethics Review Committee or IRB (Investigational Review Board) of each institution.
- The abstract involved animal experiments must meet the relevant guidelines for the care and use of laboratory animals.
Please note that if there is any doubt about the content of your presentation after the fact, you may be asked to submit an approval document.
COI (Conflict of Interest Disclosure)
All authors are required to disclose any financial relationship within the past 3 years with a biotechnology manufacturer, a pharmaceutical company, or other commercial entities that have an interest in the subject matter or materials discussed in the abstract and presentation. The matters requiring disclosure are outlined in the JSPACI Conflict of Interest Policy.
The details of COI declaration in the presentation slides will be informed on the congress website.
Personal Financial Interests
- Employment/Leadership position/Advisory role
(1,000,000 yen or more from one commercial entity) - Stock ownership or options
(Profit of 1,000,000 yen or more from one commercial entity / ownership of 5% or more of total shares of one company) - Patent royalties/licensing fees
(1,000,000 yen or more per one royalty/licensing fee) - Honoraria (e.g. lecture fees)
(500,000yen or more annually from one commercial entity) - Fees for promotional materials (e.g. Manuscript fees)
(500,000yen or more from one commercial entity) - Research funding
(1,000,000 yen or more from one commercial entity) - Scholarship donation
(1,000,000 yen or more from one commercial entity) - Endowed departments by commercial entities
(If any of the authors belongs to an endowed department sponsored by any commercial entity) - Others (e.g. trips, travel, or gifts, that are not related to research)
(50,000 yen or more from one commercial entity)
- *
- Please refer to the current currency exchange rate for Japanese Yen at an appropriate website.
How to Apply
Please register using the submission form below.
First author’s registration fee will be waived.
I-PAS Submission Form
Inquiry for Abstract Submission
If you have any questions or if submitting online is not possible, please contact the desk below.
Congress Secretariat of the 61st Annual Meeting of Japanese Society of Pediatric Allergy and Clinical Immunology
E-mail: 61jspaci[A]convention[D]co[D]jp (Please change [A]to @ and [D] to .)